Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study
S. Blanco Dorado, O. Maroñas, Ana Latorre-Pellicer, Teresa Rodríguez Jato, Ana López-Vizcaíno, Áurea María Gómez Márquez, B. Bardán García, Dolores Belles Medall, G. Barbeito Castiñeiras, M. L. Pérez Del Molino Bernal, M. Campos‐Toimil, F. O. Otero Espinar, Andrés Blanco Hortas, G. Durán Piñeiro, I. Zarra Ferro, Á. Carracedo, M. Lamas, A. Fernández-Ferreiro
{"title":"Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study","authors":"S. Blanco Dorado, O. Maroñas, Ana Latorre-Pellicer, Teresa Rodríguez Jato, Ana López-Vizcaíno, Áurea María Gómez Márquez, B. Bardán García, Dolores Belles Medall, G. Barbeito Castiñeiras, M. L. Pérez Del Molino Bernal, M. Campos‐Toimil, F. O. Otero Espinar, Andrés Blanco Hortas, G. Durán Piñeiro, I. Zarra Ferro, Á. Carracedo, M. Lamas, A. Fernández-Ferreiro","doi":"10.1002/phar.2351","DOIUrl":null,"url":null,"abstract":"Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/phar.2351","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
Abstract
Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
